Provided by Tiger Trade Technology Pte. Ltd.

Relmada Therapeutics, Inc.

4.51
+0.14503.33%
Volume:383.62K
Turnover:1.70M
Market Cap:482.04M
PE:-4.84
High:4.51
Open:4.31
Low:4.31
Close:4.36
52wk High:8.00
52wk Low:1.06
Shares:107.00M
Float Shares:78.16M
Volume Ratio:0.67
T/O Rate:0.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9300
EPS(LYR):-1.4535
ROE:-55.66%
ROA:-32.39%
PB:2.33
PE(LYR):-3.10

Loading ...

Analysts Offer Insights on Healthcare Companies: Relmada Therapeutics (RLMD), Surgery Partners (SGRY) and Apogee Therapeutics (APGE)

TIPRANKS
·
Aug 12

Piper Sandler Reaffirms Their Buy Rating on Relmada Therapeutics (RLMD)

TIPRANKS
·
Aug 07

Analysts Are Bullish on Top Healthcare Stocks: Relmada Therapeutics (RLMD), Delcath Systems (DCTH)

TIPRANKS
·
Aug 07

Relmada Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 07

Relmada Publishes Investor Presentation Highlighting NDV-01 Program for Non-Muscle Invasive Bladder Cancer

Reuters
·
Aug 07

Relmada Therapeutics Q2 EPS USD -0.11

Reuters
·
Aug 07

Press Release: Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Aug 07

Relmada Therapeutics Inc Expected to Post a Loss of 20 Cents a Share - Earnings Preview

Reuters
·
Aug 05

Relmada Therapeutics Names Bipin Dalmia Chief Business Officer

Reuters
·
Jul 28

Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer

THOMSON REUTERS
·
Jul 28

Relmada Therapeutics Schedules Q2 2026 Financial Results Call

Reuters
·
Jul 16

Mizuho Securities Remains a Buy on Relmada Therapeutics (RLMD)

TIPRANKS
·
Jul 10

Relmada Therapeutics Joins Russell 2000 Index And Russell 3000 Index

Benzinga_recent_news
·
Jun 29

Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes

GlobeNewswire
·
Jun 29

Analysts Are Bullish on These Healthcare Stocks: TScan Therapeutics (TCRX), Relmada Therapeutics (RLMD)

TIPRANKS
·
Jun 23

Relmada Therapeutics, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating

THOMSON REUTERS
·
Jun 18

Relmada names ex-Sage CSO Michael Quirk senior advisor for sepranolone program

Reuters
·
Jun 11

Press Release: Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

Dow Jones
·
Jun 11

Relmada Therapeutics raises authorized common shares to 200 million from 150 million

Reuters
·
May 29

Relmada Therapeutics - Increases Authorized Common Stock to 200 Mln Shares From 150 Mln - SEC Filing

THOMSON REUTERS
·
May 29